此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Histotripsy for Peritoneal Tumour and Lymph Node: a Pilot Study

2026年11月17日 更新者:Albert Chi Yan Chan、The University of Hong Kong

Peritoneal cancer is tricky to be managed. It is not easy to be detected or diagnosed at early stage without symptom, or with common symptoms of many diseases or discomfort and often leads to advance stage at time of diagnosis with few treatment options and limited life span. It is also challenging to handle peritoneal tumour as it usually involves large area in peritoneum, or spread widely throughout the surface of peritoneum if metastatic from other origins. Systemic therapy is the common way to treat peritoneal cacner if the disease is inoperable. However, the unsatisfied penetration rate significantly limits the anti-tumour effect of intraperitoneal chemotherapy even after various attempts and most approaches demonstrated limited efficiency. Effective treatment for peritoneal cancer is still scarce and necessary. While the tumour nature of peritoneal tumour consists of solid tumour and soft tissue tumour, depends on primary or secondary disease, Histotripsy, which can be used on most kinds of solid tumour as well as soft tissue tumour, may yield a new direction and insight on peritoneal cancer management.

Histotripsy is currently indicated for liver tumours, approved by FDA and has been investigated for many disease types in preclinical researches and carried out several clinical trials for liver tumour, benign prostatic hyperplasia, liver tumour combined with systemic therapy, renal tumour, pancreatic tumour, soft tissue tumours, abdominal tumour, calcific aortic valves, and pain in plantar fasciitis, with encouraging results in some clinical trials. As most clinical trials above are for solid tumour and soft tissue tumour that suit the tumour nature of peritoneal tumour, we believe that Histotripsy is also safe and feasible on human with peritoneal tumour. Considering nodal involvement also frequently comes with peritoneal cancer, we would like to conduct an investigation for Histotripsy in peritoneal tumour and lymph node.

Although the result of clinical trial in peritoneal tumour and lymph node are not available yet, HIFU (High Intensity Focused Ultrasound) as another non-invasive ablation also delivered by ultrasound wave which has been in clinical use for many years worldwide can be referenced for Histotripsy. The core difference of HIFU and Histotripsy is, HIFU employs thermal energy to induce coagulative necrosis, while Histotripsy utilises mechanical cavitation to disrupt tumour tissues and preserves adjacent critical structure without the issue of heat, which makes it safer than HIFU. According to some reviews of HIFU, it is obvious that HIFU is feasible and safe without significant adverse event for abdominal tumours including peritoneal tumour and lymph node. Consequently, Histotripsy as a non-thermal ablation and is considered to be safer than HIFU, should also be feasible and safe for peritoneal tumour and lymph node. Hence, it is time for Hong Kong to launch the investigation on the feasibility, safety, and efficacy of Histotripsy in peritoneal tumour and lymph node.

研究概览

地位

招聘中

研究类型

介入性

注册 (估计的)

30

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Albert Chan, MBBS, MS
  • 电话号码:+85222553025
  • 邮箱:acchan@hku.hk

学习地点

      • Hong Kong、香港、0000
        • 招聘中
        • The University of Hong Kong
        • 副研究员:
          • Vince Lau, MBBS
        • 接触:
          • Albert Chan, MBBS, MS
          • 电话号码:+85222553025
          • 邮箱:acchan@hku.hk
        • 首席研究员:
          • Albert Chan, MBBS, MS

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age ≥ 18 years old

  • Fit for general anaesthesia

  • Peritoneal tumour (eg. intraperitoneal tumour, retroperitoneal tumour) and/or lymph node

  • Size ≤ 10cm for each peritoneal tumour and lymph node

  • With or without distant metastasis

  • Good performance status

    1. Tumour visible and targetable by ultrasound with acceptable acoustic windows
    2. Adequate hematologic, hepatic, and renal function

Exclusion Criteria:

  • Refusal to take part in clinical trial
  • Not fit for general anaesthesia
  • Poor general condition with limited life expectancy
  • Uncontrolled coagulopathy
  • Extensive bowel interposition preventing safe targeting, per recent porcine safety data linking mis-targeting to bowel injury

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
其他:Histotripsy

Histotripsy is a promising non-invasive technique that uses high-intensity ultrasound waves to disrupt tissue without damaging surrounding structures

Histotripsy is a promising non-invasive technique that uses high-intensity ultrasound waves to disrupt tissue without damaging surrounding structures. It works by using high-intensity ultrasound waves to create microscopic bubbles within the tumour tissue. These bubbles rapidly expand and collapse, generating shock waves that disrupt the tissue. The technique is highly precise and can be targeted to specific areas of the liver, allowing for selective destruction of tumour cells while minimizing damage to healthy tissue.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
post procedure events
大体时间:duration of hospital stay, normally 3 days on average

safety monitoring

duration of hospital stay, normally 3 days on average
number of case proceed with Histotripsy
大体时间:1 day after procedure

feasibility of doing histotripsy for peritoneal tumour and/or lymph nodes

1 day after procedure
changes in tumour features
大体时间:up to 3 years

changes in tumour size with serial interval scans

up to 3 years

次要结果测量

结果测量
措施说明
大体时间
Questionnaire based pain assessment
大体时间:2 days

to evaluate patient-reported pain level before and after Histotripsy

2 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2029年12月31日

研究完成 (估计的)

2030年12月31日

研究注册日期

首次提交

2026年9月23日

首先提交符合 QC 标准的

2026年10月7日

首次发布 (实际的)

2026年10月14日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月17日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • GHK-2026-006

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 共享支持信息类型

  • 研究方案

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅